p53, bcl-2 and bax abnormalities in non-Hodgkin's lymphomas of the head and neck

Journal of Oral Pathology and Medicine

Volumn 29, Issue 4, 2000, Pages 180-185

  Miyauchi, Miwa ^a   Higashikawa, Koichiro ^a   Sugiyama, Masaru ^a   Harada, Tadashi ^a   Sasaki, Naomi ^b   Ishikawa, Takenori ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Kure Kyosai Hospital   (Japan)

Author keywords

B NHLs of the head and neck; bax; bcl 2; p53

Indexed keywords

BAX PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CHILD; COMPARATIVE STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEAD AND NECK TUMOR; HUMAN; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MUTATION; NONHODGKIN LYMPHOMA; PATHOLOGY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BCL-2-ASSOCIATED X PROTEIN; BURKITT LYMPHOMA; CHILD; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034071933     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0714.2000.290406.x     Document Type: Article

References (27)

1. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
2. Wheaton S, Netser J, Guinee D, et al. Bcl-2 and bax protein expression in indolent versus agressive B-cell non-Hodgkin's lymphomas. Hum Pathol 1998; 29: 820-5.
3. Martinez-Delgado B, Robledo M, Arranz E, et al. Correlation between mutations in p53 gene and protein expression in human lymphomas. Am J Hematol 1997; 55: 1-8.
4. Sander CA, Yano T, Clark HM, et al. P53 mutations are associated with progression in follicular lymphomas. Blood 1993; 82; 1994-9.
5. Lo Coco F, Gaidano G, Loine DC, et al. P53 mutations are associated with histologic transformation of follicular lymphomas. Blood 1993; 82: 2289-94.
6. Nishimura S, Asou N, Suzushima H, et al. P53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T-cell leukemia. Leukemia 1995; 9: 598-602.
7. Mckeithan, TW. Molecular biology of non-Hodgkins' lymphomas. Semin Oncol 1990; 17: 30-42.
8. McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-81.
9. Oltvai Z, Korsmeyer S. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
10. Miyashita T, Krajewski S, Krajewska MC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805.
11. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
12. Yin C, Knudson CM, Korsmeyer SJ, et al. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-40.
13. Wada M, Hosotani R, Lee JU, et al. An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. Anticancer Res 1998; 18: 2559-66.
14. Harris N, Laffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms; a proposal from the International Lymphoma Study Group. Blood 1994: 84: 1361-92.
15. Impraim CC, Saiki RK, Erlich HA, et al. Analysis of DNA extracted from formalin-fixed, paraffin-embedded tissue by enzymatic amplification and hybridization with sequence-specific oligonucleotides. Biochem Biophys Res Commun 1987; 143: 710-6.
16. Dahiya R, Deng G, Chen KM-K, et al. P53 tumor-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Br J Cancer 1996; 74: 264-8.
17. Chou D, Miyashita T, Mohrenweiser W, et al. The bax gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 1996; 88: 136-40.
18. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-termination inhibitors. Proc Natt Acad Sci USA 1977; 74: 5463-72.
19. Hollstein M, Sidransky D, Vogelstein B et al. P53 mutations in human cancers. Science 1991; 253: 49-51.
20. Fenaux P, Jonveaux P, Quiquandon I, et al. Mutation of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia 1992; 6: 42-7.
21. Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. Blood 1992; 79; 477-81.
22. Gaidano G, Ballerini P, Gong JC, et al. P53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5913-20.
23. Villuendas R, Piris MA, Algara P, et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993; 82: 3151-7.
24. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145: 1191-8.
25. Sinicrope FA, Ruan SB, Cleary KR, et al. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995; 55: 237-41.
26. Pezzella F, Morrison H, Jones M, et al. Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 1993; 22: 39-44.
27. Cooper K, Haffajee Z. Bcl-2 and p53 protein expression in follicular lymphoma. J Pathol 1997; 182: 307-10.